An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Clinical trial NCT05952557 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05952557
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-05
- Primary completion
- 2030-03-04
- Enrollment
- 5511
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.